5/14/2013 8:39:47 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Purdue Pharmaceuticals LP will shelve 90 contract sales people it used to exclusively hawk the Transcept Pharmaceuticals Inc.-developed middle-of-the-night sleep drug Intermezzo. Intermezzo will continue to be sold through Purdue's roughly 525-person analgesic sales force, Richmond-based Transcept (NASDAQ: TSPT) said Monday in a Securities and Exchange Commission filing. The 90 contract sales reps concentrate on psychiatrists and other specialty prescribers. "We're both clearly disappointed with where Intermezzo is today," Transcept COO Thomas Soloway told analysts last week.
Help employers find you! Check out all the jobs and post your resume.
comments powered by